Sign in to view content

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

Glenn J. Jaffe, MD

Video
Published 2022

Related

Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Safety of Intravitreal Pegcetacoplan in Geographic Atrophy: Results from the Phase 3 DERBY and OAKS Trials
David S. Boyer, MD
Updates from the Field
2021
Pegcetacoplan Safety: Panel Recap
Andre J. Witkin, MD
Updates from the Field
2024

Category: AMD-Non-Neovascular

See more